Multipharma launches Inceptua Medicines Access

Multipharma has launched Inceptua Medicines Access, a speciality business unit that offers access to pre-approval and unlicensed medicines.

The Luxembourg-based drug sourcing group’s new business will be split into three divisions that cover pre-approval access programmes, sourcing and supplying unlicensed medicines and strategy support services.

Peter Krantz, chief executive officer of Multipharma, said: “The establishment of Inceptua Medicines Access is the logical next step in the expansion of Multipharma, and perfectly complements the existing services supporting clinical trials of comparator sourcing, strategic planning, global depot solutions and clinical manufacturing.

“With this new addition Multipharma is poised to become a major global provider in the clinical trial services, pre-approval and unlicensed medicines space.”

All Inceptua three divisions will harness “state-of-the-art technologies” seeks to deliver medicines and investigational treatments to patients in areas that lack these facilities.

Mark Corbett, executive vice president of Inceptua Medicines Access, said: “The sector has not adapted nor kept pace with the needs of the biopharmaceutical industry, healthcare professionals and their patients worldwide.

“Current demand combined with a complex and dynamic regulatory and political landscape means we need a new way of thinking about ethical and compliant access to pre-approval and unlicensed medicines.

“We want to provide our clients and customers with a best-in-class service that makes us the go-to global provider for pre-approval and unlicensed medicines.”